Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China
Mismatch between circulating influenza B viruses and vaccine strains occurs frequently. In a randomized, double-blind, controlled phase III clinical study, healthy children aged 6-35 months were randomized into three groups at a ratio of 2:1:1, received two doses of quadrivalent influenza vaccines (...
Saved in:
Main Authors: | Yuemei Hu (Author), Ming Shao (Author), Yuansheng Hu (Author), Qi Liang (Author), Ningning Jia (Author), Kai Chu (Author), Li Xu (Author), Jing Li (Author), Changgui Li (Author), Fengcai Zhu (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
by: Shi-Yuan Wang, et al.
Published: (2017) -
Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
by: Dandan Zhu, et al.
Published: (2022) -
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
by: Jianmin Chen, et al.
Published: (2023) -
Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study
by: Yuemei Hu, et al.
Published: (2019) -
Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial
by: Timo Vesikari, et al.
Published: (2020)